Insider Transactions in Q1 2023 at Pliant Therapeutics, Inc. (PLRX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,874
-8.33%
|
$126,724
$26.52 P/Share
|
|
Mar 30
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,245
-7.16%
|
$292,370
$26.52 P/Share
|
|
Mar 30
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,036
-4.28%
|
$234,936
$26.52 P/Share
|
|
Mar 30
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
35,339
-11.4%
|
$918,814
$26.52 P/Share
|
|
Mar 30
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,960
-6.29%
|
$258,960
$26.52 P/Share
|
|
Mar 29
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
13,593
+18.84%
|
-
|
|
Mar 29
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,578
+7.69%
|
-
|
|
Mar 29
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,874
+12.23%
|
-
|
|
Mar 29
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,375
+10.9%
|
-
|
|
Mar 29
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,749
+18.15%
|
-
|
|
Feb 03
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.98%
|
$495,000
$33.72 P/Share
|
|
Feb 03
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Feb 02
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.96%
|
$510,000
$34.55 P/Share
|
|
Feb 02
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Feb 01
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.99%
|
$510,000
$34.83 P/Share
|
|
Feb 01
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Jan 31
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.88%
|
$510,000
$34.92 P/Share
|
|
Jan 31
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+2.88%
|
$60,000
$4.15 P/Share
|
|
Jan 30
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.97%
|
$510,000
$34.32 P/Share
|
|
Jan 30
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-1.19%
|
$350,000
$35.87 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.98%
|
$525,000
$35.74 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
15,000
-3.45%
|
$525,000
$35.09 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.88%
|
$525,000
$35.29 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
146,300
+37.86%
|
-
|
|
Jan 25
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,000
+29.85%
|
-
|
|
Jan 25
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+46.46%
|
-
|
|
Jan 25
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+21.93%
|
-
|
|
Jan 25
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+28.06%
|
-
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-7.0%
|
$480,000
$32.85 P/Share
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 24
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$450,000
$30.89 P/Share
|
|
Jan 24
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 23
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-26.22%
|
$1,050,000
$35.0 P/Share
|
|
Jan 23
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.34%
|
$120,000
$4.15 P/Share
|
|
Jan 23
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
67,500
-46.74%
|
$2,295,000
$34.48 P/Share
|
|
Jan 23
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
20,000
-77.08%
|
$680,000
$34.19 P/Share
|
|
Jan 23
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+33.18%
|
$360,000
$18.09 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
15,000
-3.34%
|
$525,000
$35.0 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-7.12%
|
$510,000
$34.32 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 09
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-5.06%
|
$95,000
$19.17 P/Share
|
|
Jan 09
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.82%
|
$10,000
$2.08 P/Share
|
|
Jan 06
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.04 P/Share
|
|
Jan 06
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.06 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 03
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.33 P/Share
|